Perry-Lalley D - Search Results

1

The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity.

Marcus SG, Perry-Lalley D, Mulé JJ, Rosenberg SA, Yang JC. Marcus SG, et al. Among authors: perry lalley d. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):105-12. doi: 10.1097/00002371-199402000-00003. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8136942

2

An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.

Yang JC, Perry-Lalley D, Rosenberg SA. Yang JC, et al. J Biol Response Mod. 1990 Apr;9(2):149-59. J Biol Response Mod. 1990. PMID: 1971302

3

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Bloom MB, et al. Among authors: perry lalley d. J Exp Med. 1997 Feb 3;185(3):453-9. doi: 10.1084/jem.185.3.453. J Exp Med. 1997. PMID: 9053445 Free PMC article.

4

High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. Zeh HJ 3rd, et al. Among authors: perry lalley d. J Immunol. 1999 Jan 15;162(2):989-94. J Immunol. 1999. PMID: 9916724

5

The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors.

Yang JC, Perry-Lalley D. Yang JC, et al. Among authors: perry lalley d. J Immunother. 2000 Mar-Apr;23(2):177-83. doi: 10.1097/00002371-200003000-00001. J Immunother. 2000. PMID: 10746543

6

Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.

Yang JC, Schwarz SL, Perry-Lalley DM, Rosenberg SA. Yang JC, et al. Among authors: perry lalley dm. Lymphokine Cytokine Res. 1991 Dec;10(6):475-80. Lymphokine Cytokine Res. 1991. PMID: 1804310

7

A tumor-elaborated supernatant factor chemotactic for IL-2 expanded tumor infiltrating T-lymphocytes.

Averbook BJ, Wei JP, Perry-Lalley DM, Rosenberg SA, Yang JC. Averbook BJ, et al. Among authors: perry lalley dm. Lymphokine Cytokine Res. 1993 Feb;12(1):1-8. Lymphokine Cytokine Res. 1993. PMID: 8457627

8

Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor.

Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Wang QJ, et al. Among authors: perry lalley d. J Immunother. 2005 Nov-Dec;28(6):551-9. doi: 10.1097/01.cji.0000175495.13476.1f. J Immunother. 2005. PMID: 16224272

9

Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.

Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC, Muirhead KA. Wallace PK, et al. Among authors: perry lalley d. Cancer Res. 1993 May 15;53(10 Suppl):2358-67. Cancer Res. 1993. PMID: 8485722

10

Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.

Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Hanada K, et al. Among authors: perry lalley dm. Cancer Res. 2001 Jul 15;61(14):5511-6. Cancer Res. 2001. PMID: 11454700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters